Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study
Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study have?
Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study has 0 citations in the OpenAlex counts ScholarIQ stores.
When was Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study published?
Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study has 2026 year in the ScholarIQ index.
What is the open-access status of Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study?
Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study has gold oa status in the ScholarIQ index.
What is the DOI of Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study?
The DOI for Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study is on the source record.
What is the PMID of Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study?
The PMID for Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study is on the source record.
What is the OpenAlex record for Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study?
The OpenAlex for Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study is on the source record.